Clinical trial · Observational
Circulating Tumor Cells (CTC) in Cancer
NCT04520672CI-TRIAL-00087102recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
| Samples from tumor draining vessels | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall survival (OS) in heterogeneous cancer population
- timeFrame
- Screening (Visit 1) until the date of death (assessed up to 240 months)
- description
- overall survival (OS) in heterogeneous cancer population
- measure
- Change in total number of isolated CTCs
- timeFrame
- Through study completion, an average of 20 years
- description
- Change in total number of isolated CTCs
Secondary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
- Through study completion, an average of 20 years
- description
- progression free survival (PFS) in the different cancer cohorts with different treatment regimes
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult cancer patients * All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included. * All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma * Written pathology report must be available. * Written informed consent. Exclusion Criteria: * No written informed consent. * No proved diagnosis of malignancy by pathology report. * Patients with the diagnosis of blood cancer
References
Publications (0)
Data not yet available
No reference posted for this study.